New Psychiatry and Psychopharmacology Podcast

Our partners at the Psychopharmacology Institute have recently released a podcast discussing psychiatry and psychopharmacology updates. We are sure you will find this useful, the episodes are very well edited and to the point. Click one of the links below to subscribe : Apple podcasts Google podcasts Stitcher Spotify RSS (other podcasting apps)

New Psychiatry Guidelines: Bipolar Disorder

The Psychopharmacology Institute has created a compilation of guidelines on bipolar disorder. This includes guidelines from: NICE, BAP, WFSBP and CANMAT. Find more here: Bipolar Disorder Treatment Guidelines

New Depot Antipsychotics

New long-acting (depot) antipsychotics were approved in 2015: Aristada and Invega Trinza. This practical guide from the Psychopharmacology Institute summarizes the essentials for prescribers. Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers 1 Advantages and disadvantages of long-acting antipsychotics 1.1 Potential advantages 1.2 Potential disadvantages 2 Clinical questions answered 3 Tables summarizing individual agents 3.1 […]

Methylphenidate in ADHD: Psychopharmacology

Dr. Flavio Guzman, from the Psychopharmacology Institute, recently published a new multimedia tutorial on the mechanism of action and formulations of methylphenidate. Here is the outline for the tutorial: 1 Mechanism of action 1.1 The prefrontal cortex and the role of NE and DA in ADHD 1.2 Methylphenidate inhibits the reuptake of NE and DA 2 […]

Pharmacotherapy of OCD: Interview

First-line treatments of OCD often fail. This means that for some patients, a single SSRI at optimal doses is not enough to achieve remission. In this new Psychopharmacology Institute podcast, Dr. Guzman interviews expert psychiatrist Dr. David Veale on treatment resistant-OCD. It’s interesting to learn about the role of clomipramine in the treatment algorithm. Outline Practical […]

Citalopram and Escitalopram compared

There are significant differences between these two SSRIs. The FDA warned about the risk of QT prolongation with high doses of citalopram, but not escitalopram. Dosing is different too. To learn more about these similarities and differences check the following video published at the Psychopharmacology Institute website: Citalopram and Escitalopram: A Summary of Key Differences and Similarities

Benzodiazepines mechanism of action

Benzodiazepines and GABA receptors: an animation on their mechanism of action Gamma amino butyric acid (GABA) is an inhibiting neurotransmitter that is present on human brains. As shown in the animation, gamma amino butyric acid promotes opening of a postsynaptic receptor, the GABA-A receptor. This opening leads to a increased conductance to cloride ions, which […]

Video: Side effects of SSRIs

The following video is a short overview on the pharmacological basis of SSRIs side effects. Outline: Facts about SSRIs adverse effects. Gastrointestinal adverse effects. 5-HT3 and 5-HT4 receptors in the GI tract. 5-HT3 receptors in the brainstem and hypothalamus. CNS adverse effects. 5-HT2A receptor stimulation at the basal ganglia. 5-HT2A and 2C receptors are hypothetically […]

Glutamate receptors

Overview of ionotropic (NMDA, AMPA, Kainate) and metabotropic glutamate receptors (mGluR).

Drugs for CINV prophylaxis and treatment

This article overviews the pharmacology of drugs used for the prevention and treatment of chemotherapy induced nausea and vomiting (CINV). A brief introduction on the pathophysiology is presented, to be followed by a discusssion on the different drug classes.

Clinical guidelines on CINV management

These are the latest guidelines on antiemetic managagement of chemotherapy-induced nausea and vomiting published on The Oncologist. Below that, an article from Supportive Oncology discusses the most relevant changes made in the 2006 update.